blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2209371

EP2209371 - COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.11.2017
Database last updated on 24.04.2024
FormerThe patent has been granted
Status updated on  02.12.2016
FormerGrant of patent is intended
Status updated on  23.11.2016
Most recent event   Tooltip06.03.2020Lapse of the patent in a contracting state
New state(s): TR		published on 08.04.2020  [2020/15]
Applicant(s)For all designated states
SARcode Bioscience Inc.
1000 Marina Blvd., Suite 250
Brisbane, CA 94005 / US
[2017/01]
Former [2011/44]For all designated states
SARcode Bioscience Inc.
1000 Marina Blvd., Suite 250
Brisbane, CA 94005 / US
Former [2010/30]For all designated states
Sarcode Corporation
One Embarcadero Center, Suite 2480
San Francisco, CA 94111 / US
Inventor(s)01 / BURNIER, John
One Embarcadero Center
Suite 2480
San Francisco CA 94111 / US
02 / GADEK, Thomas
One Embarcadero Center
Suite 2480
San Francisco CA 94111 / US
03 / SEMBA, Charles
One Embarcadero Center
Suite 2480
San Francisco CA 94111 / US
 [2017/01]
Former [2010/30]01 / BURNIER, John
One Embarcadero Center Suite 2480
San Francisco CA 94111 / US
02 / GADEK, Thomas
One Embarcadero Center Suite 2480
San Francisco CA 94111 / US
03 / SEMBA, Charles
One Embarcadero Center Suite 2480
San Francisco CA 94111 / US
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2017/01]
Former [2010/30]Cole, William Gwyn, et al
HLBBshaw Merlin House Falconry Court Baker's Lane
Epping, Essex CM16 5DQ / GB
Application number, filing date08842113.617.10.2008
[2010/30]
WO2008US11878
Priority number, dateUS20070999571P19.10.2007         Original published format: US 999571 P
[2010/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009054914
Date:30.04.2009
Language:EN
[2009/18]
Type: A1 Application with search report 
No.:EP2209371
Date:28.07.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 30.04.2009 takes the place of the publication of the European patent application.
[2010/30]
Type: B1 Patent specification 
No.:EP2209371
Date:04.01.2017
Language:EN
[2017/01]
Search report(s)International search report - published on:US30.04.2009
(Supplementary) European search report - dispatched on:EP06.10.2011
ClassificationIPC:A01N33/02, A61K31/14, G01N33/53, A61P27/02, A61K31/00, A61K31/198, A61K31/277, A61K31/341, A61K31/343, A61K31/381, A61K31/4025, A61K31/472, A61K31/4725, A61K31/496, A61K31/502, A61K31/517, A61K31/66, A61K45/06, A61K9/00
[2011/44]
CPC:
A61P41/00 (EP); A61K49/00 (US); A61F9/0017 (US);
A61K31/14 (EP,US); A61K31/198 (EP,US); A61K31/277 (EP,US);
A61K31/341 (EP,US); A61K31/343 (EP,US); A61K31/381 (EP,US);
A61K31/4025 (EP,US); A61K31/472 (EP,US); A61K31/4725 (EP,US);
A61K31/496 (EP,US); A61K31/502 (EP,US); A61K31/517 (EP,US);
A61K31/66 (EP,US); A61K39/39533 (US); A61K45/06 (EP,US);
A61K9/0014 (EP,US); A61K9/0048 (US); A61K9/06 (US);
A61K9/08 (US); A61P27/02 (EP); A61P3/10 (EP);
A61P43/00 (EP); A61P9/10 (EP); C07K16/2821 (US);
G01N33/6893 (US); A61K2039/505 (US); A61K2039/507 (US);
C07K2317/92 (US); G01N2333/70503 (US); G01N2333/70525 (US);
G01N2800/042 (US); G01N2800/164 (US); Y02A50/30 (EP) (-)
Former IPC [2010/30]A01N33/02, A61K31/14, G01N33/53
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/01]
Former [2010/30]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON DIABETISCHER RETINOPATHIE[2010/30]
English:COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY[2010/30]
French:COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE[2010/30]
Entry into regional phase12.05.2010National basic fee paid 
12.05.2010Search fee paid 
12.05.2010Designation fee(s) paid 
12.05.2010Examination fee paid 
Examination procedure12.05.2010Examination requested  [2010/30]
26.03.2012Amendment by applicant (claims and/or description)
25.02.2013Despatch of a communication from the examining division (Time limit: M06)
05.09.2013Reply to a communication from the examining division
13.04.2015Despatch of a communication from the examining division (Time limit: M06)
07.10.2015Reply to a communication from the examining division
16.09.2016Communication of intention to grant the patent
22.11.2016Fee for grant paid
22.11.2016Fee for publishing/printing paid
22.11.2016Receipt of the translation of the claim(s)
Divisional application(s)EP16204718.7  / EP3167886
EP20189143.9
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.02.2013
Opposition(s)05.10.2017No opposition filed within time limit [2017/50]
Fees paidRenewal fee
25.10.2010Renewal fee patent year 03
25.10.2011Renewal fee patent year 04
25.10.2012Renewal fee patent year 05
28.10.2013Renewal fee patent year 06
27.10.2014Renewal fee patent year 07
27.10.2015Renewal fee patent year 08
27.10.2016Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.10.2008
AT04.01.2017
CY04.01.2017
CZ04.01.2017
DK04.01.2017
EE04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
MC04.01.2017
PL04.01.2017
RO04.01.2017
SE04.01.2017
SI04.01.2017
SK04.01.2017
TR04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
[2020/15]
Former [2019/46]HU17.10.2008
AT04.01.2017
CY04.01.2017
CZ04.01.2017
DK04.01.2017
EE04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
MC04.01.2017
PL04.01.2017
RO04.01.2017
SE04.01.2017
SI04.01.2017
SK04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
Former [2019/31]HU17.10.2008
AT04.01.2017
CZ04.01.2017
DK04.01.2017
EE04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
MC04.01.2017
PL04.01.2017
RO04.01.2017
SE04.01.2017
SI04.01.2017
SK04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
Former [2018/29]AT04.01.2017
CZ04.01.2017
DK04.01.2017
EE04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
MC04.01.2017
PL04.01.2017
RO04.01.2017
SE04.01.2017
SI04.01.2017
SK04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
Former [2018/14]AT04.01.2017
CZ04.01.2017
DK04.01.2017
EE04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
PL04.01.2017
RO04.01.2017
SE04.01.2017
SI04.01.2017
SK04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
Former [2017/50]AT04.01.2017
CZ04.01.2017
DK04.01.2017
EE04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
PL04.01.2017
RO04.01.2017
SE04.01.2017
SK04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
Former [2017/49]AT04.01.2017
CZ04.01.2017
EE04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
PL04.01.2017
RO04.01.2017
SE04.01.2017
SK04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
Former [2017/48]AT04.01.2017
CZ04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
PL04.01.2017
SE04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
Former [2017/41]AT04.01.2017
FI04.01.2017
HR04.01.2017
LT04.01.2017
LV04.01.2017
PL04.01.2017
SE04.01.2017
BG04.04.2017
NO04.04.2017
GR05.04.2017
IS04.05.2017
PT04.05.2017
Documents cited:Search[X]WO2005080373  (PFIZER PROD INC [US], et al) [X] 1-4,10-15 * page 55, line 14 - page 56, line 31 * * table 9a * * compound 113 * * claim 21 *;
 [XI]EP1396490  (YAMANOUCHI PHARMA CO LTD [JP]) [X] 1-4,10-12,14,15 * paragraphs [0001] , [0010] , [0063] , [0076]; compounds 146,182 * [I] 13;
 [XI]JP2007099641  ;
 [A]US2007048216  (NORENBERG JEFFREY P [US]) [A] 1-5,8,10-15 * paragraphs [0023] , [0061] , [0064]; claims 23,27 *;
 [A]WO2007039286  (NOVARTIS AG [CH], et al) [A] 1-5,8,10-15 * paragraphs [0218] , [0221] , [0226] *;
 [A]US2006281820  (SODA KUNIYASU [JP]) [A] 1-5,8,10-15 * paragraphs [0011] , [0012] , [0024] , [0025] * * paragraphs [0033] - [0035] - [0161] , [0234] * * paragraphs [0235] , [0236] * * claims 25-27 *;
 [Y]WO2005044817  (SUNESIS PHARMACEUTICALS INC [US], et al) [Y] 1-5,8,10-15 * paragraphs [0006] , [0043] , [0047] , [0181] , [0182] , [0184] , [0191]; claims 60-71 *;
 [Y]US2004028648  (ADAMIS ANTHONY P [US]) [Y] 1-5,8,10-15 * paragraphs [0007] , [0016] , [0038] , [0054] * * paragraph [0075] * * example - * * claims 1,3 *
 [XI]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2007, no. 46, Database accession no. 2007-471921, XP002660009 & JP2007099641 A 20070419 (TSUMURA & CO) [X] 1-4,10-12,14,15 * abstract * * paragraphs [0012] , [0028] , [0057]; compound 1.10 * [I] 13
International search[X]US2006281739  (GADEK THOMAS [US], et al);
 [X]US2004028648  (ADAMIS ANTHONY P [US])
Examination   - RAO V R ET AL, "Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE 2010 ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY INC. USA, (201010), vol. 51, no. 10, ISSN 0146-0404, pages 5198 - 5204
by applicantUS2004028648
 US5747035
 US5843885
 US6630447
 US7314938
 US6667318
 US6872735
 US6803384
 US7217728
 US6331640
 US6515124
 US2005203135
 US2008234271
 US2004116518
 US2005014746
 US2002156314
 US2002132807
 US2008249157
 US2007066585
 US2008108677
 US2008242710
 US6630492
 US6818638
 US2006148836
 US2006142319
 US2006074099
 US2006052434
 US2005119279
 US2005004153
 US2004259897
 US2004248920
 US2004009998
 US2002143035
 US2002119994
 US2004058968
 US2005080119
 WO9949856
 WO0021920
 WO0158853
 WO02059114
 WO2005044817
 US7166568
 US6319897
 US5843884
 US5135916
 US5624837
 US5023252
 US4992445
 US5001139
 US6488916
    - A. M. JOUSSEN; T. MURATA; A. TSUJIKAWA; B. KIRCHOF; S-E. BURSELL; A. P. ADAMIS, "Leukocyte- Mediated Endothelial Cell Injury and Death in the Diabetic Retina", A, J. PATHOL., (2001), vol. 158, no. 1, pages 147 - 162
    - S. M. BERGE ET AL., J PHARMACEUTICAL SCIENCES, (1977), vol. 66, pages 1 - 19
    - T. HIGUCHI; V. STELLA, Pro-drugs as Novel Delivery Systems, A. C. S. SYMPOSIUM SERIES, vol. 14
    - S.M. KEATING; K.R. CLARK; L. D. STEPANICH; F. ARELLANO; C. P. EDWARDS; S.C. BODARY; S. A. SPENCER; T. R. GADEK; J. C, MARSTERS JR., "Competition between intercellualr adhesion molecule- and a small molecule antagonist for a common binding site on the al subunit of lymphocyte function-associated antigen-1", PROTEIN SCIENCE, (2006), vol. 15, doi:doi:10.1110/ps.051583406, pages 290 - 303, XP002522873

DOI:   http://dx.doi.org/10.1110/ps.051583406
    - KUYPERS T.W.; ROOS D., "Leukocyte membrane adhesion proteins LFA-1, CR3 and pl50,95: a review of functional and regulatory aspects", RES. IMMUNOL., (1989), vol. 140, pages 461 - 465
    - FISCHER A; DURANDY A; STERKERS G; GRISCELLI C, "Role of the LFA- molecule in cellular interactions required for antibody production in humans", J. IMMUNOL., (1986), vol. 136, page 3198
    - SANDERS VM; SNYDER JM; UHR JW; VITETTA ES, "Characterization of the physical interaction between antigen-specific B and T cells", J. IMMUNOL., (1986), vol. 137, page 2395
    - MENTZER SJ; GROMKOWSKI SH; KRENSKY AM; BURAKOFF SJ; MARTZ E., "LFA-1 membrane molecule in the regulation of homotypic adhesions of human B lymphocytesn", J. IMMUNOL., (1985), vol. 135, page 9
    - LO SK; VAN SEVENTER GA; LEVIN SM; WRIGHT SD., "Two leukocyte receptors (CD1 la/CD18 and CD1 lb/CD18) mediate transient adhesion to endothelium by binding to different ligands", J. IMMUNOL., (1989), vol. 143, page 3325
    - LU, C; SHIMAOKA, M.; SALAS, A.; SPRINGER, T.A., "The Binding Sites for Competitive Antagonistic, Allosteric Antagonistic, and Agonistic Antibodies to the I Domain of Integrin LFA-1", J. IMMUN., (2004), vol. 173, pages 3972 - 3978, XP002461643
    - LIU, G.; LINK, J.T.; PEI, Z.; REILLY, E.B.; NGUYEN, B.; MARSH, K.C.; OKASINSKI, G.F.; VON GELDERN, T.W.; ORMES, M.; FOWLER, K., "Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule- interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead", J. MED. CHEM., (2000), vol. 43, pages 4015 - 4030
    - KALLEN, J.; WELZENBACH, K.; RAMAGE, P.; GEYL, D.; KRIWACKI, R.; LEGGE, G.; COTTENS, S.; WEITZ-SCHMIDT, G.; HOMMEL, U., "Structural basis for LFA- inhibition upon lovastatin binding to the CD11a I-domain", J. MOL. BIOL., (1999), vol. 292, doi:doi:10.1006/jmbi.1999.3047, pages 1 - 9, XP004461886

DOI:   http://dx.doi.org/10.1006/jmbi.1999.3047
    - WEITZ-SCHMIDT, G.; WELZENBACH, K.; BRINKMANN, V.; KAMATA, T.; KALLEN, J.; BRUNS, C.; COTTENS, S.; TAKADA, Y.; HOMMEL, U., "Statins selectively inhibit leukocyte function antigen- by binding to a novel regulatory integrin site", NATURE MED., (2001), vol. 7, pages 687 - 692
    - FRENETTE, P. S., "Locking a leukocyte integrin with statins", N. ENGL. J. MED., (2001), vol. 345, pages 1419 - 1421
    - WELZENBACH, K.; HOMMEL, U.; WEITZ-SCHMIDT,G., "Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of Lymphocyte Function-Associated Antigen-1", J. BIOL. CHEM., (2002), vol. 277, pages 10590 - 10598
    - KELLY, T. A.; JEANFAVRE, D. D.; MCNEIL, D. W.; WOSKA, J. R. JR.; REILLY, P. L.; MAINOLFI, E. A.; KISHIMOTO, K. M.; NABOZNY, G. H.;, "Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion", J. IMMUNOL., (1999), vol. 163, pages 5173 - 5177, XP002171606
    - GADEK, T. R.; BURDICK, D. J.; MCDOWELL, R. S.; STANLEY, M. S.; MARSTERS, J. C. JR.; PARIS, K. J.; OARE, D. A.; REYNOLDS, M. E.; LA, "Generation of an LFA- antagonist by the transfer of the ICAM- immunoregulatory epitope to a small molecule", SCIENCE, (2002), vol. 295, doi:doi:10.1126/science.295.5557.1086, pages 1086 - 1089, XP002522872

DOI:   http://dx.doi.org/10.1126/science.295.5557.1086
    - The Science and Practice of Pharmacy, LIPPINCOTT WILLIAMS & WILKINS
    - KLAUSNER, E.A.; LAVY, E.; BARTA, M.; CSEREPES, E.; FRIEDMAN, M.; HOFFMAN, A., "Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa in humans", PHARM. RES., (2003), vol. 20, pages 1466 - 73
    - HOFFMAN, A.; STEPENSKY, D.; LAVY, E.; EYAL, S.; KLAUSNER, E.; FRIEDMAN, M., "Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms", INT. J. PHARM., (2004), vol. 11, pages 141 - 53
    - STREUBEL, A.; SIEPMANN, J.; BODMEIER, R., "Gastroretentive drug delivery systems", EXPERT OPIN. DRUG DELIVER., (2006), vol. 3, doi:doi:10.1517/17425247.3.2.217, pages 217 - 3, XP009093467

DOI:   http://dx.doi.org/10.1517/17425247.3.2.217
    - LANDEGREN, U., J. IMMUNOL. METHODS, (1984), vol. 57, pages 379 - 388
    - SKELLY ET AL., "FDA and AAPS Report of the Workshop on Principles and Practices of In-Vitro Percutaneous Penetration Studies: Relevance to Bioavailability and Bioequivalence", PHARMACEUTICAL RESEARCH, (1987), vol. 4, no. 3, pages 265 - 276
    - NATURE, (1990), vol. 346, page 425
    - A. J. CUNNINGHAM, UNDERSTANDING IMMUNOLOGY, TRANSPLANTATION IMMUNOLOGY, (1978), pages 157 - 159
    - S. P. AYALASOMAYAJULA; U. B. KOMPELLA, EUROPEAN JOURNAL OF PHARMACOLOGY, (2003), vol. 458, pages 283 - 289
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.